Galvanize PEF System 2024 Reimbursement And Coding User Guide
Galvanize PEF System 2024 Reimbursement And Coding

BACKGROUND

ABOUT ALIYA SYSTEM FOR PULSED FIELD ABLATION OF SOFT TISSUE

The Aliya™ system is designed to ablate soft tissue through the delivery of pulsed electric fields (PEF) energy to target tissue. The high frequency, short duration energy is delivered to the target tissue to induce cell death while maintaining the extracellular matrix.

INDICATIONS FOR USE

The Aliya system is 510(k) cleared in the United States for the surgical ablation of soft tissue.

DISCLAIMER

Galvanize Therapeutics does not promote the off-label use of its products and nothing herein is intended to promote an off-label use of the Aliya System. The Aliya System is a tool for the surgical ablation of soft tissues, and is not intended to treat, cure, prevent or mitigate any specific disease or condition.
The information provided contains general reimbursement information and is presented for illustrative purposes. The information does not constitute reimbursement or legal advice. It is the provider’s sole responsibility to determine medical necessity, the proper site for delivery of any services, and to submit accurate and appropriate codes, charges and modifiers based on the services rendered and the patient’s medical condition.
It is also the provider‘s sole responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other specific payer billing requirements established by relevant payers. Payer billing, coding and coverage requirements vary from payer to payer, may be updated frequently, and should be verified before treatment for limitations on diagnosis, coding, or service requirements. Galvanize Therapeutics recommends you consult with payers, reimbursement specialists, and/or legal counsel regarding all coding, coverage, and reimbursement matters. All coding and
billing submissions to the federal government and any other payer must be truthful and not misleading, and require full disclosure for the reimbursement of any service or procedure. Galvanize Therapeutics specifically disclaims any responsibility for actions or consequences resulting from the use of this information.

CPT® Copyright 2024 American Medical Association. All rights reserved CPT® is a trademark of the American
Medical Association. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not necessarily recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. All trademarks are the property of their respective owners.

DISCLOSURE

Prior to using the Aliya System, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. For full prescribing information, please visit www.galvanizetherapeutics.com.

PHYSICIAN, HOSPITAL OUTPATIENT, AND ASC CODING

Medicare 2024 National Average Payment (Not Adjusted Geographically)
Service ProvidedPhysician Fee Schedule1  ASC2Payment/IndicatorHospital3
CPT® DescriptionNon-Facility (OBL)Facility (-26)APC/Indicator APC/ IndicatorOPPSPayment
0600T*Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous (Do not report 0600T in conjunction with 76940, 77002, 77013, 77022)No national payment established$ 6604J85362 J1$9808
0601T*Ablation, irreversible electroporation; 1 or more tumors, including fluoroscopic and ultrasound guidance, when performed, open (Do not report 0601T in conjunction with 76940, 77002)No national payment established$ 6 4 81J85362J1$9808

*2024 CPT® Professional. Current Procedural Terminology (CPT®) is copyright 1966, 1970, 1973, 1977, 1981, 1983-2022 by the American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association (AMA).

CATEGORY III CPT® CODES

The Aliya PEF procedure may be reported using the Category III CPT® codes in the table above. These codes
specifically describe irreversible electroporation of tumors via a percutaneous or open approach. If any
other type of laproscopic, endoscopic, or bronchoscopic approach is performed an unlisted procedure code
may be reported. Unlisted CPT® codes or “not otherwise specified” CPT® codes allow physicians to report
procedures that do not have a more specific CPT® code. Reporting an unlisted code correctly with appropriate
documentation allows physicians and hospitals to submit coding for a procedure that does not have a specific
CPT® code. The procedures described by CPT® 0600T and 0601T include the imaging guidance procedures. Imaging guidance CPT® codes are not separately submitted on the CMS Form 1500 claim form.

Category III CPT® Codes are temporary codes for emerging technology, services and procedures that allow
for specific data collection associated with those services and procedures. According to the AMA CPT®, if a Category III code is available, it must be reported instead of a Category I unlisted code1 .
There are no assigned RVU’s or established physician payment for these Category III CPT® codes.
Reimbursement to the physician is at the payer’s discretion. Payers may request documentation of clinical efficacy to support coverage. Payers that have implemented the new Category III IRE codes may request documentation of clinical efficacy to support coverage. The following items are recommended to support your claim submissions:

  • Copy of operative report
  • Letter of medical necessity
  • Copy of the FDA clearance letter

When submitting a Category III CPT® code, it is recommended that providers submit a narrative listing a Category I CPT® code that they feel is comparable in time, effort, complexity, and value to the service provided, suggesting that the payer value the service represented by the Category III CPT® code based on the value assigned to this comparable Category I CPT® code. It will be important to document the services provided in terms of resources and time for appropriate payment consideration for the professional component of the procedure.

THE CODES BELOW DO NOT PRESUME, ASSUME, OR INTEND TO PROMOTE THE USE OF THIS GENERAL TOOL IN ANY SPECIFIC ANATOMICAL LOCATION OR FOR ANY SPECIFIC TREAMENT BY THE HEALTHCARE PROVIDER. THIS REIMBURSEMENT GUIDE IS ONLY INTENDED TO IDENTIFY GENERAL SOFT TISSUE LOCATIONS.

KIDNEY ICD-10-PCS CODES AND MS-DRGS

ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024) 

The listed ICD-10-PCS codes are examples of codes that may apply for kidney ablation procedures.4 Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5

CodeICD-10-PCS Description4MS-DRG5
0T500ZZDestruction of right kidney, open approach656 – 661
0T503ZZDestruction of right kidney, percutaneous approach656 – 661
0T504ZZDestruction of right kidney, percutaneous endoscopic approach656 – 661
0T510ZZDestruction of left kidney, open approach656 – 661
0T513ZZDestruction of left kidney, percutaneous approach656 – 661
0T514ZZDestruction of left kidney, percutaneous endoscopic approach656 – 661
0T530ZZDestruction of right kidney pelvis, open approach656 – 661
0T533ZZDestruction of right kidney pelvis, percutaneous approach656 – 661
0T534ZZDestruction of right kidney pelvis, percutaneous endoscopic approach656 – 661
0T540ZZDestruction of left kidney pelvis, open approach656 – 661
0T543ZZDestruction of left kidney pelvis, percutaneous approach656 – 661
0T544ZZDestruction of left kidney pelvis, percutaneous endoscopic approach656 – 661

Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to kidney ablation procedures for Medicare patients. Other secondary diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.

MS-DRG5MS-DRG DescriptionRelative Weight         Hospital Payment
656KIDNEY & URETER PROCEDURES FOR NEOPLASM W/ MCC3 . 1 3 76$21,968
657KIDNEY & URETER PROCEDURES FOR NEOPLASM W/ CC1 . 8 4 42$ 12 ,9 12
658KIDNEY & URETER PROCEDURES FOR NEOPLASM W/O CC/MCC1 . 4 8 04$10,365
659KIDNEY & URETER PROCEDURES FOR NON-NEOPLASM W/ MCC2 . 58 89$ 1 8 ,126
660KIDNEY & URETER PROCEDURES FOR NON-NEOPLASM W/ CC1 . 3 4 59$ 9 , 4 2 3
661KIDNEY & URETER PROCEDURES FOR NON-NEOPLASM W/O CC/MCC1 .0 4 8 4$ 7, 3 4 0

ICD-10-CM7 Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for kidney ablation procedures.

CodeICD-10-CM Description (Diagnosis Codes)
C64.1Malignant neoplasm of right kidney, except renal pelvis
C64.2Malignant neoplasm of left kidney, except renal pelvis
C64.9Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1Malignant neoplasm of right renal pelvis
C65.2Malignant neoplasm of left renal pelvis
C65.9Malignant neoplasm of unspecified renal pelvis
C79.00Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.01Secondary malignant neoplasm of right kidney and renal pelvis
C79.02Secondary malignant neoplasm of left kidney and renal pelvis
C7A.093Malignant carcinoid tumor of the kidney
C80.2Malignant neoplasm associated with transplanted organ

LIVER ICD-10-PCS CODES AND MS-DRGS

ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for liver ablation procedures.4 Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5

CodeICD-10-PCS Description4MS-DRG5
0F500ZFDestruction of liver using irreversible electroporation, open approach356-358,  405-407
0F503ZFDestruction of liver using irreversible electroporation, percutaneous approach356-358,  405-407
0F504ZFDestruction of liver using irreversible electroporation, percutaneous endoscopic approach356-358,  405-407
0F510ZFDestruction of right lobe liver using irreversible electroporation, open approach356-358,  405-407
0F513ZFDestruction of right lobe liver using irreversible electroporation, percutaneous approach356-358,  405-407
0F514ZFDestruction of right lobe liver using irreversible electroporation, percutaneous endoscopic approach356-358,  405-407
0F520FZDestruction of left lobe liver using irreversible electroporation, open approach356-358,  405-407
0F523FZDestruction of left lobe liver using irreversible electroporation, percutaneous approach356-358,  405-407
0F524FZDestruction of left lobe liver using irreversible electroporation, percutaneous endoscopic approach356-358,  405-407

Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to liver ablation procedures for Medicare patients. Other secondary diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.

MS-DRG5MS-DRG DescriptionRelative Weight         Hospital Payment
356OTHER DIGESTIVE SYSTEM O.R. PROCEDURES W/ MCC4 . 2787$29,958
357OTHER DIGESTIVE SYSTEM O.R. PROCEDURES W/ CC2 .1 9 6 8$ 15 , 381
358OTHER DIGESTIVE SYSTEM O.R. PROCEDURES W/O CC/MCC1 . 28 1 1$ 8 , 9 7 0
405PANCREAS, LIVER & SHUNT PROCEDURES W/ MCC5 . 5052$38,545
406PANCREAS, LIVER & SHUNT PROCEDURES W/ CC2 . 8 874$20, 216
407PANCREAS, LIVER & SHUNT PROCEDURES W/O CC/MCC2 . 1 5 1 0$15,060

ICD-10-CM7Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for liver ablation procedures.

CodeICD-10-CM Description (Diagnosis Codes)
C22.0Liver cell carcinoma
C22.1Intrahepatic bile duct carcinoma
C22.2Hepatoblastoma
C22.3Angiosarcoma of liver
C22.4Other sarcomas of liver
C22.7Other specified carcinomas of liver
C22.8Malignant neoplasm of liver, primary, unspecified as to type
C22.9Malignant neoplasm of liver, not specified as primary or secondary
C78.7Secondary malignant neoplasm of liver and intrahepatic bile duct
C7A.098Malignant carcinoid tumors of other sites
C7A.1Malignant poorly differentiated neuroendocrine tumors
C7A.8Other malignant neuroendocrine tumors
C7B.02Secondary carcinoid tumors of liver
C7B.8Other secondary neuroendocrine tumors
D01.5Carcinoma in situ of liver, gallbladder and bile ducts

LUNG ICD-10-PCS CODES AND MS-DRGS

ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for lung ablation procedures.4 0Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5

CodeICD-10-PCS Description4MS-DRG5
0B533ZZDestruction of Right Main Bronchus, Percutaneous Approach163 – 165
0B543ZZDestruction of Right Upper Lobe Bronchus, Percutaneous Approach163 – 165
0B553ZZDestruction of Right Middle Lobe Bronchus, Percutaneous Approach163 – 165
0B563ZZDestruction of Right Lower Lobe Bronchus, Percutaneous Approach163 – 165
0B573ZZDestruction of Left Main Bronchus, Percutaneous Approach163 – 165
0B583ZZDestruction of Left Upper Lobe Bronchus, Percutaneous Approach163 – 165
0B593ZZDestruction of Lingula Bronchus, Percutaneous Approach163 – 165
0B5B3ZZDestruction of Left Lower Lobe Bronchus, Percutaneous Approach163 – 165
0B5C3ZZDestruction of Right Upper Lung Lobe, Percutaneous Approach166 – 168
0B5D3ZZDestruction of Right Middle Lung Lobe, Percutaneous Approach166 – 168
0B5F3ZZDestruction of Right Lower Lung Lobe, Percutaneous Approach166 – 168
0B5G3ZZDestruction of Left Upper Lung Lobe, Percutaneous Approach166 – 168
0B5H3ZZDestruction of Lung Lingula, Percutaneous Approach166 – 168
0B5J3ZZDestruction of Left Lower Lung Lobe, Percutaneous Approach166 – 168
0B5K3ZZDestruction of Right Lung, Percutaneous Approach166 – 168
0B5L3ZZDestruction of Left Lung, Percutaneous Approach166 – 168
0B5M3ZZDestruction of Bilateral Lungs, Percutaneous Approach166 – 168
0B5N3ZZDestruction of Right Pleura, Percutaneous Approach163 – 165
0B5P3ZZDestruction of Left Pleura, Percutaneous Approach163 – 165
0B5T3ZZDestruction of Diaphragm, Percutaneous Approach163 – 165
0B5_0ZZDestruction of [see above], Open Approach163 – 165

Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to lung ablation procedures for Medicare patients. Other secondary diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.

MS-DRG3MS-DRG DescriptionRelative Weight         Hospital Payment
163MAJOR CHEST PROCEDURES W/ MCC4 . 7 13 6$33,003
164MAJOR CHEST PROCEDURES W/ CC2.5504$1 7, 85 7
165MAJOR CHEST PROCEDURES W/O CC/MCC1.8 76 4$ 13 , 13 8
166OTHER RESP SYSTEM O.R. PROCEDURES W/MCC4.0578$ 2 8 , 41 1
167OTHER RESP SYSTEM O.R. PROCEDURES W/ CC1 . 8198$ 12 , 742
168OTHER RESP SYSTEM O.R. PROCEDURES W/O CC/MCC1 . 35 5 7$ 94 9 2

ICD-10-CM7Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for lung ablation procedures.

CodeICD-10-PCS Description4
C34.00Malignant neoplasm of unspecified main bronchus
C34.01Malignant neoplasm of right main bronchus
C34.02Malignant neoplasm of left main bronchus
C34.10Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11Malignant neoplasm of upper lobe, right bronchus or lung
C34.12Malignant neoplasm of upper lobe, left bronchus or lung
C34.2Malignant neoplasm of middle lobe, bronchus or lung
C34.30Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31Malignant neoplasm of lower lobe, right bronchus or lung
C34.32Malignant neoplasm of lower lobe, left bronchus or lung
C34.80Malignant neoplasm of overlapping sites, unspecified bronchus or lung
C34.81Malignant neoplasm of overlapping sites, right bronchus or lung
C34.82Malignant neoplasm of overlapping sites, left bronchus or lung
C34.90Malignant neoplasm of unspecified part, unspecified bronchus or lung
C34.91Malignant neoplasm of unspecified part, right bronchus or lung
C34.92Malignant neoplasm of unspecified part, left bronchus or lung
C37Malignant neoplasm of thymus
C38.4Malignant neoplasm of pleura
C45.0Mesothelioma of pleura
C76.1Malignant neoplasm of thorax
C78.00Secondary malignant neoplasm of unspecified lung
C78.01Secondary malignant neoplasm of right lung
C78.02Secondary malignant neoplasm of left lung
C78.1Secondary malignant neoplasm of mediastinum
C7A.090Malignant carcinoid tumor of the bronchus and lung
C7A.091Malignant carcinoid tumor of the thymus
D02.20Carcinoma in situ of unspecified bronchus and lung
D02.21Carcinoma in situ of right bronchus and lung
D02.22Carcinoma in situ of left bronchus and lung
D38.1Neoplasm of uncertain behavior of trachea, bronchus and lung
D38.2Neoplasm of uncertain behavior of pleura
D38.3Neoplasm of uncertain behavior of mediastinum
D38.4Neoplasm of uncertain behavior of thymus

PANCREAS ICD-10-PCS CODES AND MS-DRGS

ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for pancreas ablation procedures.4 Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5

CodeICD-10-PCS Description4MS-DRG5
0F5G0ZFDestruction of pancreas using irreversible electroporation, open approach405-407, 628-630
0F5G3ZFDestruction of pancreas using irreversible electroporation, percutaneous approach405-407, 628-630
0F5G4ZFDestruction of pancreas using irreversible electroporation, percutaneous endoscopic approach

Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to pancreas ablation procedures for Medicare patients. Other secondary 0diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.

MS-DRG3MS-DRG DescriptionRelative Weight         Hospital Payment
405PANCREAS, LIVER, & SHUNT PROCEDURES W/ MCC5 . 5052$38,545
406PANCREAS, LIVER, & SHUNT PROCEDURES W/ CC2 . 8 874$20,216
407PANCREAS, LIVER, & SHUNT PROCEDURES W/O CC/MCC2 . 1 5 1 0$15,060
628OTHER ENDOCRINE, NUTRIT & METAB O.R. PROC W/ MCC4 .01 4 5$28,108
629OTHER ENDOCRINE, NUTRIT & METAB O.R. PROC W/ CC2 . 2628$15,843
630OTHER ENDOCRINE, NUTRIT & METAB O.R. PROC W/O CC/MCC1 . 39 6 3$ 9, 7 7 6

ICD-10-CM7Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for pancreas ablation procedures.

MS-DRG3ICD-10-CM Description (Diagnosis Codes)
C25.0Malignant neoplasm of head of pancreas
C25.1Malignant neoplasm of body of pancreas
C25.2Malignant neoplasm of tail of pancreas
C25.3Malignant neoplasm of pancreatic duct
C25.4Malignant neoplasm of endocrine pancreas
C25.7Malignant neoplasm of other parts of pancreas
C25.8Malignant neoplasm of overlapping sites of pancreas
C25.9Malignant neoplasm of pancreas, unspecified

REIMBURSEMENT SUPPORT

For questions regarding coding, coverage, payment and other reimbursement information, please contacts us at: AliyaReimbursement@galvanizetx.com.

REIMBURSEMENT TERMINOLOGY

TermDescription
CMSCenters for Medicare and Medicaid Services
ASCAmbulatory Surgical Center
OPPSOutpatient Prospective Payment System
APCAmbulatory Payment Classification
  J1Paid under OPPS; all covered Part B services on the claim are packaged with the primary “J1” service for the claim, except services with OPPS status indicator of “F,” “G,” “H,” “L” and “U”; ambulance services; diagnostic and screening mammography; rehabilitation therapy services; services assigned to a new technology APC; self- administered drugs; all preventive services; and certain Part B inpatient services.
J8Device-intensive procedure; paid at adjusted rate
ICD-10-CMInternational Classification of Diseases, 10th Revision, Clinical Modification
ICD-10-PCSInternational Classification of Diseases, 10th Revision, Procedure Coding System
IPPSInpatient Prospective Payment System
MS-DRGMedicare Severity Diagnosis Related Group
W/MCCMajor Complications and Comorbidities
W/CCWith Complications and Comorbidities
W/O CC/MCCWithout Complications or Comorbidities, and Without Major Complications and Comorbidities.
Relative WeightA numeric value that reflects the relative resource consumption for the DRG to which it is assigned

SOURCES

  1. CMS Physician Fee Schedule. CMS-1784-F. https://www.cms.gov/medicare/medicare-fee-service payment/physicianfeesched/ puffs-federal-regulation-notices/cms-1784-f
  2. CMS ASC Payment. CMS-1786-FC ASC. https://www.cms.gov/medicare/payment/prospective-payment systems/ambulatory surgical-center-ask/ask-regulations-and/cms-1786-fc
  3. CMS OPPS Payment. CMS-1786-FC. https://www.cms.gov/medicare/payment/prospective-payment systems/hospitaloutpatient/regulations-notices/cms-1786-fc
  4. CMS, 2024 ICD-10 Procedure Coding System (ICD-10-PCS). https://www.cms.gov/medicare/coding billing/icd-10-codes/2024- icd-10-pcs
  5. CMS, 2024 ICD-10-CM/PCS MS-DRG v41, Definitions Manual. https://www.cms.gov/icd10m/FY2024 nprmversion41.0-fullcodecms/fullcode_cms/P0001.html
  6. CMS, [CMS-1785-F] 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) Final Rule; Federal Register.
    https://www.govinfo.gov/content/pkg/FR-2023-08-28/pdf/2023-16252.pdf. Payment is calculated based on the national adjusted standardized amount $7,001.60. Actual Medicare payment rates will vary from adjustments by Wage Index and Geographic Adjustment Factor depending on geographic locality. Also note that any applicable coinsurance, deductible, and other amounts that are patient obligations are included in the payment amount shown.
  7. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). https://www.cdc.gov/nchs/icd/icd-10 cm.htm. Updated June 29, 2023.

CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician. Important information: Prior to use, refer to the Instructions for Use that are supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. Galvanize and Aliya are trademarks and may be registered in the US and/or in other countries.
All rights reserved.
SLS-00022 Rev D 2/21/2024
3200 Bridge Pkwy Redwood City, CA 94065
Galvanizetherapeutics.com

Company Logo

Documents / Resources

Galvanize PEF System 2024 Reimbursement And Coding [pdf] User Guide
PEF System, PEF System 2024 Reimbursement And Coding, PEF System, 2024 Reimbursement And Coding, Reimbursement And Coding, And Coding, Coding

References

Leave a comment

Your email address will not be published. Required fields are marked *